164 related articles for article (PubMed ID: 23099322)
1. Fasudil suppresses fibrosarcoma growth by stimulating secretion of the chemokine CXCL14/BRAK.
Miyamoto C; Maehata Y; Ozawa S; Ikoma T; Kubota E; Izukuri K; Kato Y; Hata R; Lee MC
J Pharmacol Sci; 2012; 120(3):241-9. PubMed ID: 23099322
[TBL] [Abstract][Full Text] [Related]
2. Fasudil, a Rho kinase inhibitor, suppresses tumor growth by inducing CXCL14/BRAK in head and neck squamous cell carcinoma.
Miyamoto C; Maehata Y; Motohashi K; Ozawa S; Ikoma T; Hidaka K; Wada-Takahashi S; Takahashi SS; Yoshino F; Yoshida A; Kubota E; Hata R; Lee MC
Biomed Res; 2014; 35(6):381-8. PubMed ID: 25743344
[TBL] [Abstract][Full Text] [Related]
3. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models.
Ying H; Biroc SL; Li WW; Alicke B; Xuan JA; Pagila R; Ohashi Y; Okada T; Kamata Y; Dinter H
Mol Cancer Ther; 2006 Sep; 5(9):2158-64. PubMed ID: 16985048
[TBL] [Abstract][Full Text] [Related]
4. Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo.
Deng L; Li G; Li R; Liu Q; He Q; Zhang J
Cancer Biol Ther; 2010 Jun; 9(11):875-84. PubMed ID: 20364104
[TBL] [Abstract][Full Text] [Related]
5. Chemokine CXCL14/BRAK transgenic mice suppress growth of carcinoma cell transplants. [corrected].
Izukuri K; Suzuki K; Yajima N; Ozawa S; Ito S; Kubota E; Hata R
Transgenic Res; 2010 Dec; 19(6):1109-17. PubMed ID: 20333465
[TBL] [Abstract][Full Text] [Related]
6. Rho Kinase Inhibitor Fasudil Suppresses the Vasculogenic Mimicry of B16 Mouse Melanoma Cells Both In Vitro and In Vivo.
Xia Y; Cai XY; Fan JQ; Zhang LL; Ren JH; Chen J; Li ZY; Zhang RG; Zhu F; Wu G
Mol Cancer Ther; 2015 Jul; 14(7):1582-90. PubMed ID: 25934709
[TBL] [Abstract][Full Text] [Related]
7. RhoA/ROCK pathway inhibition by fasudil suppresses the vasculogenic mimicry of U2OS osteosarcoma cells in vitro.
Xia Y; Cai X; Fan J; Zhang L; Li Z; Ren J; Wu G; Zhu F
Anticancer Drugs; 2017 Jun; 28(5):514-521. PubMed ID: 28225457
[TBL] [Abstract][Full Text] [Related]
8. Expression of tumour-suppressing chemokine BRAK/CXCL14 reduces cell migration rate of HSC-3 tongue carcinoma cells and stimulates attachment to collagen and formation of elongated focal adhesions in vitro.
Sato K; Ozawa S; Izukuri K; Kato Y; Hata R
Cell Biol Int; 2010 Apr; 34(5):513-22. PubMed ID: 20067447
[TBL] [Abstract][Full Text] [Related]
9. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses 5-hydroxytryptamine-induced pulmonary artery smooth muscle cell proliferation via JNK and ERK1/2 pathway.
Chen XY; Dun JN; Miao QF; Zhang YJ
Pharmacology; 2009; 83(2):67-79. PubMed ID: 19052484
[TBL] [Abstract][Full Text] [Related]
10. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control.
Kolavennu V; Zeng L; Peng H; Wang Y; Danesh FR
Diabetes; 2008 Mar; 57(3):714-23. PubMed ID: 18083785
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of fasudil on renal interstitial fibrosis induced by unilateral ureteral obstruction.
Baba I; Egi Y; Utsumi H; Kakimoto T; Suzuki K
Mol Med Rep; 2015 Dec; 12(6):8010-20. PubMed ID: 26498136
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of fasudil, a Rho-kinase inhibitor, on chemokine expression, leukocyte recruitment, and hepatocellular apoptosis in septic liver injury.
Thorlacius K; Slotta JE; Laschke MW; Wang Y; Menger MD; Jeppsson B; Thorlacius H
J Leukoc Biol; 2006 May; 79(5):923-31. PubMed ID: 16641138
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the Rho/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1α in human ovarian cancer cells.
Ohta T; Takahashi T; Shibuya T; Amita M; Henmi N; Takahashi K; Kurachi H
Cancer Biol Ther; 2012 Jan; 13(1):25-33. PubMed ID: 22336585
[TBL] [Abstract][Full Text] [Related]
14. Fasudil alleviates acetaminophen-induced liver injury via targeting Rhoa/ROCK signal pathway.
Ren X; Meng T; Ren X; Li X; Lu L
J Toxicol Sci; 2021; 46(6):255-262. PubMed ID: 34078832
[TBL] [Abstract][Full Text] [Related]
15. Rho Kinase Inhibition by Fasudil Attenuates Adriamycin-Induced Chronic Heart Injury.
Yan Y; Xiang C; Yang Z; Miao D; Zhang D
Cardiovasc Toxicol; 2020 Aug; 20(4):351-360. PubMed ID: 31894538
[TBL] [Abstract][Full Text] [Related]
16. Fasudil, an inhibitor of Rho-associated coiled-coil kinase, improves cognitive impairments induced by smoke exposure.
Xueyang D; Zhanqiang M; Chunhua M; Kun H
Oncotarget; 2016 Nov; 7(48):78764-78772. PubMed ID: 27791202
[TBL] [Abstract][Full Text] [Related]
17. Could pharmacological curtailment of the RhoA/Rho-kinase pathway reverse the endothelial barrier dysfunction associated with Ebola virus infection?
Eisa-Beygi S; Wen XY
Antiviral Res; 2015 Feb; 114():53-6. PubMed ID: 25512227
[TBL] [Abstract][Full Text] [Related]
18. Rho kinase inhibitor fasudil suppresses migration and invasion though down-regulating the expression of VEGF in lung cancer cell line A549.
Zhu F; Zhang Z; Wu G; Li Z; Zhang R; Ren J; Nong L
Med Oncol; 2011 Jun; 28(2):565-71. PubMed ID: 20300976
[TBL] [Abstract][Full Text] [Related]
19. RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations.
Shenkar R; Shi C; Austin C; Moore T; Lightle R; Cao Y; Zhang L; Wu M; Zeineddine HA; Girard R; McDonald DA; Rorrer A; Gallione C; Pytel P; Liao JK; Marchuk DA; Awad IA
Stroke; 2017 Jan; 48(1):187-194. PubMed ID: 27879448
[TBL] [Abstract][Full Text] [Related]
20. Rho kinase inhibition by fasudil attenuates cyclosporine-induced kidney injury.
Park JW; Park CH; Kim IJ; Bae EH; Ma SK; Lee JU; Kim SW
J Pharmacol Exp Ther; 2011 Jul; 338(1):271-9. PubMed ID: 21474569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
